Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and automimmune disorders. The company’s portfolio of antibody-drug conjugates are aimed to specific payload of a chemotherapeutic directly to the tumor. Its clinical stage candidates include Sacituzumab govitecan (IMMU-132); Labetuzumab Govitecan (IMMU-130); and Epratuzumab. Other candidates in early stage development include IMMU-114; milatuzumab; veltuzumab; and Yttrium-90-Labeled Epratuzumab Tetraxetan. The company develops its candidates based on its proprietary technologies namely, ADC Linker technology; Pretargeting and Dock-And-Lock platform. Immunomedics also manufactures and commercializes diagnostic imaging product named, LeukoScan. It has collaborations with UCB and Center for Molecular Medicine and Immunology (CMMI) for the development of its candidates. Immunomedics is headquartered in Morris Plains, New Jersey, the US.
Immunomedics Inc Key Recent Developments Aug 16,2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline May 10,2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments May 05,2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value Feb 21,2017: Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws Feb 09,2017: Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments
Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 33 molecules. Out of which approximately 29 molecules...
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018 Summary Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 22 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Post Menopausal Osteoporosis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2018, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape. Postmenopausal...
